Aposense Ltd. - Product Pipeline Review - 2014
PR Newswire - Thu Nov 20, 6:47AM CST
Summary
Global Colon Carcinoma Therapeutics Pipeline Report 2014 - 5 Companies & 15 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl8zck/colon_carcinoma) has announced the addition of the "Colon Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aposense Ltd. - Teva Pharmaceutical Industries Limited - Patrys Limited - Philogen S.p.A. - AIMM Therapeutics B.V. Drug Profiles - CEP-37250 - PAT-LM1 - ATT-11T - CIGB-247 - Antibody for Oncology - Small Molecules to Inhibit Tubulin for Oncology - Monoclonal Antibody for Colon Carcinoma - methoxynaphthylfenoterol - Vaccine for Lymphoma and Colon Carcinoma - Recombinant Protein to Activate IL-2 Receptor for Oncology - Adhesio-mAb - Anti-MFG-E8 Mab - F8IL-4 - Peptide for Colon Carcinoma - Antibody to Inhibit Rspo2 and Rspo3 for Oncology For more information visit http://www.researchandmarkets.com/research/sl..._carcinoma
TEVA: 57.09 (+0.33)